ALAMAR BIOSCIENCES INC
ALMRNASDAQTrading Snapshot
- Day Range
- $36.06 – $37.27
- 52-Week Range
- $18.85 – $29.43
- Volume
- $3.87B
- Avg Volume
- $3.42B
- Shares Outstanding
- 69.3M
- Next Earnings
- Oct 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.06B
- Last Q Revenue
- $283M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own ALMR
- ✓High-growth profile — revenue up +47.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 34% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ALAMAR BIOSCIENCES INC
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
What's going on in today's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Here are the top movers in Tuesday's session.
Looking for insights into the US markets in the middle of the day on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Stifel Maintains Buy on Alamar Biosciences, Raises Price Target to $32
Stifel analyst Daniel Arias maintains Alamar Biosciences (NASDAQ:ALMR) with a Buy and raises the price target from $28 to $32.
Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum
Alamar Biosciences expands its Alzheimer’s data partnership, adds 86,000 samples and reports Q2 sales growth of 82% year-over-year.
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release, Q2 earnings
JP Morgan Maintains Overweight on Alamar Biosciences, Raises Price Target to $35
JP Morgan analyst Casey Woodring maintains Alamar Biosciences (NASDAQ:ALMR) with a Overweight and raises the price target from $32 to $35.